New Pitt Startups in Fiscal Year 2022
Activity Rhythm Solutions Corporation: Using circadian rest/activity rhythm data gathered by a wearable device to monitor for risk of health outcomes such as depression, and improve our ability to provide adaptive interventions
Avista Therapeutics: Recently entered into a development agreement for its next-generation gene therapies for blindness with the major pharmaceutical company Roche
BioSystics, Inc.: Analytics platform analyzes and computationally models complex data sets to create outcomes to accelerate and optimize basic biomedical research, drug discovery/development and preclinical trials as well as cosmetic, industrial and environmental chemical testing
Elio AI, Inc.: Delivering medical-imaging AI that is intuitive and understandable to clinicians for reliable, real-time AI diagnosis and treatment guidance for a range of crucial clinical applications, including ultrasound trauma assessment, tumor classification and biopsy, and ophthalmology
GenexGen: New generation of immune-suppressive therapies for improving the safety of CRISPR-based gene therapy
HENY, Inc.: An early stage startup building a decentralized biobank to empower patients, incentivize research collaboration and unlock the future of precision medicine
Legal Triage: Web-based legal database that helps individuals navigate legal summaries impacting volunteer participation in preparing for or responding to disasters
MDR Therapeutics LLC: Platform-based vaccine technology that elicits first-in-class bacteria-specific mucosal immune responses, including both T cell and B cell responses, providing dual levels of protection against pneumonia
Painimation: Technology-based pain assessment tool to help patients communicate their pain experience and provide clinicians with the needed information to accurately diagnose and treat pain symptoms
Reach Neuro, Inc.: Medical device solutions to fight chronic disability
Remplir Bio: Developing novel immunotherapy drugs for cancer that alter the metabolism of immune cells and the way that immune cells “see” their local environment, resulting in increased immune activity in cancer
Synhale: Developing drugs to address the molecular origins of pulmonary arterial hypertension
